ALM-223 is under development for the treatment of systemic lupus erythematosus (SLE) and atopic dermatitis (AD). It is administered through subcutaneous route in the form of liquid. It is a fusion ...

Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

A history of infertility without fertility treatment was associated with a higher future risk of SARD, independent of co-existing adverse pregnancy outcomes.

Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found ...

The increased risks for arterial thrombotic events (ATE), venous thromboembolism (VTE), and all-cause mortality known to be ...

The intricate link between endocrine disorders and cancer development has drawn significant interest, revealing how conditions like insulin resistance and ...

Nkarta focuses on autoimmune diseases, with $402.5M in cash. Read why NKTX stock, currently undervalued, offers multiple ...

Caribou Biosciences, Inc. data from phase 1 ANTLER study is expected in 1H 2025. Click here to find out why I'm neutral on ...

The prevalence of fibromyalgia is higher among patients with SLE vs the general population, adding to an already significant ...

I started taking Plaquenil, which is very hard on my digestive system. I get severe gas pains in my chest for a couple of ...

"Incomplete lupus" is a term used to describe a person who has some symptoms of lupus but not enough to make the diagnosis ...